Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Trial · NCT03640481
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Adult Arm A: Belumosudil 200 mg QD | 74.0 | Percentage of participants | ||
| Overall Response Rate (ORR) | Adult Arm B: Belumosudil 200 mg BID | 76.0 | Percentage of participants | ||
| Overall Response Rate (ORR) | Adolescent Arm A: Belumosudil 200 mg QD | 50.0 | Percentage of participants | ||
| Overall Response Rate (ORR) | Adolescent Arm B: Belumosudil 200 mg BID | 100.0 | Percentage of participants | ||
| Duration of Response (DOR) | Adult Arm A: Belumosudil 200 mg QD | 23.9 | 95% Confidence Interval 11.43 to 50.43 | Weeks | |
| Duration of Response (DOR) | Adult Arm B: Belumosudil 200 mg BID | 32.0 | 95% Confidence Interval 20.86 to 53.14 | Weeks | |
| Duration of Response (DOR) | Adolescent Arm A: Belumosudil 200 mg QD | 16.1 | 95% Confidence Interval NA to NA | Weeks | |
| Duration of Response (DOR) | Adolescent Arm B: Belumosudil 200 mg BID | 4.1 | 95% Confidence Interval NA to NA | Weeks | |
| Number of Participants With Improvement (>=7-Point Reduction [7-PtR] From Baseline) as Assessed by Lee Symptom Scale (LSS) Score | Adult Arm A: Belumosudil 200 mg QD | 45 | Participants | ||
| Number of Participants With Improvement (>=7-Point Reduction [7-PtR] From Baseline) as Assessed by Lee Symptom Scale (LSS) Score | Adult Arm B: Belumosudil 200 mg BID | 48 | Participants | ||
| Number of Participants With Improvement (>=7-Point Reduction [7-PtR] From Baseline) as Assessed by Lee Symptom Scale (LSS) Score | Adolescent Arm A: Belumosudil 200 mg QD | 0 | Participants | ||
| Number of Participants With Improvement (>=7-Point Reduction [7-PtR] From Baseline) as Assessed by Lee Symptom Scale (LSS) Score | Adolescent Arm B: Belumosudil 200 mg BID | 0 | Participants | ||
| Number of Participants With Best Response by Organ System | Adult Arm A: Belumosudil 200 mg QD | Skin | 20 | Participants | |
| Number of Participants With Best Response by Organ System | Adult Arm B: Belumosudil 200 mg BID | Skin | 28 | Participants | |
| Number of Participants With Best Response by Organ System | Adolescent Arm A: Belumosudil 200 mg QD | Skin | 1 | Participants | |
| Number of Participants With Best Response by Organ System | Adult Arm A: Belumosudil 200 mg QD | Eyes | 24 | Participants | |
| Number of Participants With Best Response by Organ System | Adult Arm B: Belumosudil 200 mg BID | Eyes | 26 | Participants | |
| Number of Participants With Best Response by Organ System | Adolescent Arm B: Belumosudil 200 mg BID | Eyes | 1 | Participants | |
| Number of Participants With Best Response by Organ System | Adult Arm A: Belumosudil 200 mg QD | Mouth | 23 | Participants | |
| Number of Participants With Best Response by Organ System | Adult Arm B: Belumosudil 200 mg BID | Mouth | 31 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03640481/results